-
Mashup Score: 0
As requested by the FDA, a new biologics license application including updated scientific rationale has been submitted for remestemcel-L as treatment for patients with steroid-refractory acute graft-vs-host disease.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal cardiac arrhythmia syndrome triggered by catecholamines released during exercise, stress, or sudden em
Source: Circulation ResearchCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Researchers at the Wroclaw Medical University in Poland investigated the use of vedolizumab for steroid-resistant (SR) gastrointestinal (GI) acute graft-versus-host disease (aGVHD) in children. Their preliminary findings, published in the journal Advances in Clinical and Experimental Medicine, demonstrate the vedolizumab may be used in children with SR GI aGVHD. Allogeneic hematopoietic stem…
Source: ASTCT NucleusCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Background: Oxidative stress in cardiac disease promotes proarrhythmic disturbances in Ca2+ homeostasis, impairing luminal Ca2+ regulation of the sarcoplasmic reticulum (SR) Ca2+ release channel, the
Source: Circulation ResearchCategories: Cardiology News and Journals, Latest HeadlinesTweet
The biologics license application for remestemcel-L has been resubmitted to the #FDA for the treatment of pediatric patients with steroid-refractory acute graft-vs-host disease. #SR-aGVHD. #GVHD | @DukeMedSchool @DukeHealth https://t.co/G3k7Uh20qG